Wuhan Biofriend Technology Co.,Ltd

Top Grade Biotechnology Manufacturer In China

Quality Product Safe Delivery Professional Service

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsSex Enhancing Drugs

Flibanserin White Powder Sex Enhancement Drugs for Females

Good quality Injectable Anabolic Steroids for sales
Good quality Injectable Anabolic Steroids for sales
Everything is perfect!The quality,prices and shipping!I will buy from you every month.

—— Carlos

The package is complete when i have it!Everything are perfect!Thank you Corleone and i will be keeping ordering!!

—— Blaker

I'm Online Chat Now

Flibanserin White Powder Sex Enhancement Drugs for Females

China Flibanserin White Powder Sex Enhancement Drugs for Females supplier
Flibanserin White Powder Sex Enhancement Drugs for Females supplier Flibanserin White Powder Sex Enhancement Drugs for Females supplier

Large Image :  Flibanserin White Powder Sex Enhancement Drugs for Females

Product Details:

Place of Origin: Wuhan
Brand Name: Biofriend
Certification: SGS,ISO9001,UKAS,GMP
Model Number: 167933-07-5

Payment & Shipping Terms:

Minimum Order Quantity: 10g
Price: Negotiable
Packaging Details: Discreet ways of packing for customs guaranteed
Delivery Time: Within 24 hours after payment
Payment Terms: T/T, Western Union, MoneyGram,Bitcoin,Paypal
Supply Ability: 2000kg Per Month
Contact Now
Detailed Product Description
MF: C20H21F3N4O MW: 390.40
Purity: 99.5% Appearance: White Powder
Grade: Pharmaceutical Grade Packing:: Aluminum Foil Bag

Flibanserin White Powder Sex Enhancement Drugs for Females

 

CAS 167933-07-5 Flibanserin
 
Product Name:Flibanserin
CAS NO.:167933-07-5
Molecular Formula:C20H21F3N4O
Molecular Weight:390.40
Purity:99%
Grade:Pharmaceutical Grade
Appearance:White powder
Flibanserin White Powder Sex Enhancement Drugs for Females
 
Why is this medication prescribed?
 
Flibanserin is used to treat women with hypoactive sexual desire disorder (HSDD; a low sexual desire that causes distress or interpersonal difficulty) who have not experienced menopause (change of life; the end of monthly menstrual periods). Flibanserin should not be used for the treatment of HSDD in women who have gone through menopause or in men or to improve sexual performance. Flibanserin is in a class of medications called a serotonin receptor 1A agonist/serotonin receptor 2A antagonist. It works by changing the activity of serotonin and other natural substances in the brain.
 
Flibanserin,sold under the trade name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD).The medication increases the number of satisfying sexual events per month by about one half to one over placebo from a starting point of about two to three.
 
Flibanserin is used for hypoactive sexual desire disorder among women. Those receiving flibanserin report that the average number of times they had “satisfying sexual events” rose from 2.8 to 4.5 times a month. However, women receiving placebo reported also an increase of “satisfying sexual events” from 2.7 to 3.7 times a month. Evaluation of the overall improvement of their condition and whether the benefit was meaningful to the women, showed a significantly higher rate of a meaningful benefit in the flibanserin-treated people versus the placebo group.The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.
 
The effectiveness of flibanserin was evaluated in three phase 3 clinical trials. Each of the three trials had two co-primary endpoints, one for satisfying sexual events (SSEs) and the other for sexual desire. Each of the 3 trials also had a secondary endpoint that measured distress related to sexual desire.
 
All three trials showed that flibanserin produced a statistically significant increase in the number of SSEs and reduced distress related to sexual desire.
 
The first two trials used an electronic diary to measure sexual desire, and did not find a statistically significant increase relative to women treated with a placebo. These two trials also measured sexual desire using the Female Sexual Function index (FSFI) as a secondary endpoint, and a statistically significant increase was observed using this latter measure. The FSFI was used as the co-primary endpoint for sexual desire in the third trial, and again showed a statistically significant increase.

Contact Details
Wuhan Biofriend Technology Co.,Ltd

Contact Person: Ian

Send your inquiry directly to us (0 / 3000)